Literature DB >> 9706971

Acral myxoinflammatory fibroblastic sarcoma: a low-grade tumor of the hands and feet.

J M Meis-Kindblom1, L G Kindblom.   

Abstract

Acral myxoinflammatory fibroblastic sarcoma is a unique low-grade tumor of modified fibroblasts. It characteristically occurs in the distal extremities and has a propensity to recur locally. Forty-four cases that occurred in 22 males and 22 females from 20 to 91 years of age (median, 53 years) were studied. The lesions, which were 1-6 cm (median, 3 cm), occurred in the hands (64%), the feet (20%), the ankles (11%), and the wrists (5%). The patients usually had a long history of a painless mass (median duration, 1 year). Clinically they were suspected to be ganglion cysts, tenosyonovitis, or giant cell tumors of tendon sheath. Initial histologic diagnoses, in most cases, included pigmented villonodular tenosynovitis or various reactive fibroinflammatory processes. Histologically, the lesions were multinodular, poorly delineated, and characterized by a prominent myxoid matrix containing numerous inflammatory cells, including polymorphonuclear leukocytes, eosinophils, lymphocytes, and plasma cells, as well as fibrosis. Amidst the prominent inflammation, and sometimes obscured by it, were scattered, large, bizarre tumor cells with vesicular nuclei, prominent inclusion-like nucleoli, and abundant eosinophilic cytoplasm, which was homogeneous to vacuolated and often contained intracytoplasmic inflammatory cells. Ultrastructurally, the bizarre tumor cells had features of modified fibroblasts, including an abundance of intermediate filaments and dilated rough endoplasmic reticulum. Immunohistochemically, the neoplastic cells revealed strong positivity for vimentin (25 of 25), focal positivity for CD68 antigen (17 of 25) and CD34 (7 of 25); the tumor cells did not express neuroectodermal, epithelial, or lymphoid markers. The Ki67 labeling index with MIB1 was less than 1% in 20 of 25 cases; p53 immunoreactivity (20-90%) was observed in 7 of 25 primary tumors and in 2 of 3 local recurrences. Follow-up information was available in 36 of 44 cases (median, 5 years). Most excisions were either intralesional or marginal. Ten patients underwent amputation, usually after repeated local recurrences. Radiation therapy and chemotherapy were administered in five and two cases, respectively. Twenty-four cases (67%) had at least one local recurrence. A histologically proven lymph node metastasis developed in one patient, whereas another was stated to have lung metastases, although these were not documented histologically. At last follow-up, 23 patients were alive and well, 11 were alive with disease, and 2 were dead of other causes without evidence of tumor. The prominent inflammation and fibrosis seen histologically in acral myxoinflammatory fibroblastic sarcoma simulate a reactive process. The presence of myxoid foci and scattered bizarre cells, which are occasionally multivacuolated, may cause confusion with malignant fibrous histiocytoma and liposarcoma. Based on the protracted clinical course, a high rate of local recurrence (sometimes necessitating amputation), and a low rate of metastasis, we believe these tumors are low-grade sarcomas. The intimate relationship with the synovium, the frequent association with tenosynovitis, and the prominent inflammatory infiltrate suggest that inflammation may play a role in the pathogenesis of acral myxoinflammatory fibroblastic sarcoma.

Entities:  

Mesh:

Year:  1998        PMID: 9706971     DOI: 10.1097/00000478-199808000-00001

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  24 in total

1.  Pleomorphic hyalinizing angiectatic tumor: imaging findings.

Authors:  Ty K Subhawong; Andrea P Subhawong; Elizabeth A Montgomery; Laura M Fayad
Journal:  Skeletal Radiol       Date:  2012-06-03       Impact factor: 2.199

Review 2.  Myxoinflammatory fibroblastic sarcoma: investigations by comparative genomic hybridization of two cases and review of the literature.

Authors:  Daniel Baumhoer; Kathrin Glatz; Hans-Jürgen Schulten; László Füzesi; Renato Fricker; Christoph Kettelhack; Paula Hasenboehler; Martin Oberholzer; Gernot Jundt
Journal:  Virchows Arch       Date:  2007-08-11       Impact factor: 4.064

3.  Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome.

Authors:  William B Laskin; John F Fetsch; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

4.  Consistent t(1;10) with rearrangements of TGFBR3 and MGEA5 in both myxoinflammatory fibroblastic sarcoma and hemosiderotic fibrolipomatous tumor.

Authors:  Cristina R Antonescu; Lei Zhang; G Petur Nielsen; Andrew E Rosenberg; Paola Dal Cin; Christopher D M Fletcher
Journal:  Genes Chromosomes Cancer       Date:  2011-06-29       Impact factor: 5.006

5.  Myxoinflammatory fibroblastic sarcoma in the chest wall.

Authors:  Kyoung Shik Narm; In Kyu Park; Mi Kyung Bae; Gi Jeong Kim
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2012-02-07

Review 6.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

7.  Recurrent BRAF Gene Rearrangements in Myxoinflammatory Fibroblastic Sarcomas, but Not Hemosiderotic Fibrolipomatous Tumors.

Authors:  Yu-Chien Kao; Valentina Ranucci; Lei Zhang; Yun-Shao Sung; Edward A Athanasian; David Swanson; Brendan C Dickson; Cristina R Antonescu
Journal:  Am J Surg Pathol       Date:  2017-11       Impact factor: 6.394

8.  VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer.

Authors:  Karen Gambaro; Michael C J Quinn; Paulina M Wojnarowicz; Suzanna L Arcand; Manon de Ladurantaye; Véronique Barrès; Jean-Sébastien Ripeau; Ann M Killary; Elaine C Davis; Josée Lavoie; Diane M Provencher; Anne-Marie Mes-Masson; Mario Chevrette; Patricia N Tonin
Journal:  Mol Oncol       Date:  2013-01-16       Impact factor: 6.603

9.  Acral myxoinflammatory fibroblastic sarcoma: A case report and literature review.

Authors:  Andrew G Silver; Richard C Baynosa; Raman C Mahabir; Wei Z Wang; William A Zamboni; Kayvan T Khiabani
Journal:  Can J Plast Surg       Date:  2013

10.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.